Anti-Dengue Virus NS1 Protein Monoclonal Antibodies

Technology #18262

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Experimental data from lateral flow assays indicating that the 725-323/724-626 pair is specific for dengue virus 4. This pair is reversible. Experimental data from lateral flow control assays indicating that the antibody pairs indicated in the figure do not cross react with the purified yellow fever virus. Recombinant NS1 protein purchased from the Native Antigen Company (UK).
Professor Lee Gehrke
Institute for Medical Engineering & Science, MIT
External Link (
Kimberly Hamad-Schifferli
Department of Mechanical Engineering, MIT
Jose Gomez-Marquez
Institute for Medical Engineering & Science, MIT
Irene Bosch
Institute for Medical Engineering & Science, MIT
Managed By
Tod Woolf
MIT Technology Licensing Officer
Patent Protection

Anti-Dengue Virus NS1 Protein Monoclonal Antibodies

US Patent Pending

Anti-Dengue Virus NS1 Protein Monoclonal Antibodies

PCT Patent Application Filed


This technology may be used to detect dengue virus infections.

Problem Addressed

Dengue fever and the more severe dengue hemorrhagic fever and dengue shock syndrome are caused by the mosquito-borne dengue virus. It is estimated that 50-100 million people are infected with dengue virus annually and that 2.5 billion people are currently at risk for contracting this dangerous pathogen. Dengue virus has four antigenically distinct serotypes, so those infected with one serotype do not develop immunity to the others despite extensive cross-reactivity in serological tests. Further, increased risk of severe complications occurs with infection of more than one serotype. Accurate diagnosis of dengue virus serotypes is critical to individual patient care and proper outbreak management. Dengue virus serotypes are quite distinct at a nucleic acid level, so nucleic acid detection techniques (PCR) can distinguish the serotypes with high sensitivity. However, these techniques are not always possible in rugged environments because they require laboratory environments, special reagents, and skilled technicians. This technology includes a set of novel pairs of monoclonal antibodies that can be used provide accurate and specific diagnosis of infection by each of the four dengue serotypes in assays that are amenable to rugged environments.


This invention comprises matched capture/detection monoclonal antibody pairs that can distinguish between the different dengue virus serotypes and detect one or more of these serotypes in a biological sample. The target antigen is the NS1 glycoprotein. This invention includes diagnostic detection kits for dengue virus. Lateral flow assays are recommended but detection labels are flexible.  


  • Antibodies compatible with a large number of detection labels
  • Highly-specific antibodies can distinguish between different serotypes of dengue as well as yellow fever and Zika viruses¬†without cross-reactivity from the NS1 protein from yellow fever or Zika viruses
  • Accurate detection of serotypes allows study of virus infection dynamics as well as individual patient treatment and improved outbreak management